...
首页> 外文期刊>Journal of cellular and molecular medicine. >Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1
【24h】

Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1

机译:西地那非介导的新生血管形成和对大鼠心肌缺血再灌注损伤的保护:VEGF /血管生成素-1的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Sildenafil citrate (SC), a drug for erectile dysfunction, is now emerging as a cardiopulmonary drug. Our study aimed to determine a novel role of sildenafil on cardioprotection through stimulating angiogenesis during ischaemia (I) reperfusion (R) at both capillary and arteriolar levels and to examine the role of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) in this mechanistic effect. Rats were divided into: control sham (CS), sildenafil sham (SS), control + IR (CIR) and sildenafil + IR (SIR). Rats were given 0.7 mg/kg, (i.v) of SC or saline 30 min. before occlusion of left anterior descending artery followed by reperfusion (R). Sildenafil treatment increased capillary and arteriolar density followed by increased blood flow (2-fold) compared to control. Treatment with sildenafil demonstrated increased VEGF and Ang-1 mRNA after early reperfusion. PCR data were validated by Western blot analysis. Significant reduction in infarct size, cardiomyocyte and endothelial apoptosis were observed in SC-treated rats. Increased phosphorylation of Akt, eNOS and expression of anti-apoptotic protein Bcl-2, and thioredoxin, hemeoxygenase-1 were observed in SC-treated rats. Echocardiography demonstrated increased fractional shortening and ejection fraction following 45 days of reperfusion in the treatment group. Stress testing with dobutamine infusion and echocardiogram revealed increased contractile reserve in the treatment group. Our study demonstrated for the first time a strong additional therapeutic potential of sildenafil by up-regulating VEGF and Ang-1 system, probably by stimulating a cascade of events leading to neovascularization and conferring myocardial protection in in vivo I/R rat model.
机译:枸酸西地那非(SC)是一种勃起功能障碍的药物,目前正作为一种心肺药物出现。我们的研究旨在确定西地那非在毛细血管和小动脉水平上通过刺激局部缺血(I)再灌注(R)期间的血管新生来在心血管保护中发挥新作用,并研究血管内皮生长因子(VEGF)和血管生成素1(Ang- 1)在这种机械作用下。将大鼠分为:假手术(CS),西地那非假手术(SS),对照+ IR(CIR)和西地那非+ IR(SIR)。在30分钟内给大鼠0.7毫克/千克(i.v)的SC或生理盐水。在闭塞左前降支动脉之前,然后进行再灌注(R)。与对照相比,西地那非治疗增加了毛细血管和小动脉的密度,随后增加了血流量(2倍)。西地那非治疗表明早期再灌注后VEGF和Ang-1 mRNA升高。 PCR数据通过Western印迹分析验证。在SC治疗的大鼠中观察到梗塞面积,心肌细胞和内皮细胞凋亡的显着减少。在经SC处理的大鼠中观察到Akt,eNOS的磷酸化增加以及抗凋亡蛋白Bcl-2和硫氧还蛋白,血红素加氧酶-1的表达。超声心动图显示治疗组再灌注45天后,缩短和射血分数增加。用多巴酚丁胺输注和超声心动图进行压力测试显示,治疗组的收缩储备增加。我们的研究首次证明了通过上调VEGF和Ang-1系统可能增强了西地那非的强大治疗潜力,这可能是通过刺激一系列导致新生血管形成的事件并在体内I / R大鼠模型中赋予心肌保护来实现的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号